Brokerages expect that Kura Oncology Inc (NASDAQ:KURA) will post earnings per share of ($0.42) for the current quarter, according to Zacks. Zero analysts have made estimates for Kura Oncology’s earnings, with estimates ranging from ($0.49) to ($0.38). Kura Oncology also posted earnings of ($0.42) per share during the same quarter last year. The firm is scheduled to announce its next earnings results on Tuesday, March 3rd.
On average, analysts expect that Kura Oncology will report full year earnings of ($1.53) per share for the current year, with EPS estimates ranging from ($1.61) to ($1.50). For the next fiscal year, analysts expect that the company will post earnings of ($1.93) per share, with EPS estimates ranging from ($2.26) to ($1.40). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Kura Oncology.
Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03.
Shares of NASDAQ:KURA traded down $0.46 during midday trading on Monday, reaching $15.48. 262,701 shares of the company traded hands, compared to its average volume of 260,401. The company has a quick ratio of 19.29, a current ratio of 19.29 and a debt-to-equity ratio of 0.03. Kura Oncology has a 12 month low of $12.30 and a 12 month high of $21.42. The firm has a market capitalization of $722.32 million, a price-to-earnings ratio of -9.00 and a beta of 2.56. The firm’s fifty day moving average price is $14.93 and its two-hundred day moving average price is $16.84.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Great Point Partners LLC increased its stake in Kura Oncology by 1.3% in the 3rd quarter. Great Point Partners LLC now owns 3,086,053 shares of the company’s stock worth $46,815,000 after acquiring an additional 38,253 shares during the last quarter. BlackRock Inc. increased its stake in Kura Oncology by 2.6% in the 2nd quarter. BlackRock Inc. now owns 2,407,038 shares of the company’s stock worth $47,396,000 after acquiring an additional 61,255 shares during the last quarter. Eagle Asset Management Inc. increased its stake in Kura Oncology by 1.6% in the 3rd quarter. Eagle Asset Management Inc. now owns 2,075,747 shares of the company’s stock worth $31,489,000 after acquiring an additional 31,878 shares during the last quarter. Vanguard Group Inc. increased its stake in Kura Oncology by 23.0% in the 2nd quarter. Vanguard Group Inc. now owns 2,012,548 shares of the company’s stock worth $39,628,000 after acquiring an additional 376,172 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in Kura Oncology by 12.0% in the 2nd quarter. Victory Capital Management Inc. now owns 1,967,270 shares of the company’s stock worth $38,736,000 after acquiring an additional 210,900 shares during the last quarter. Institutional investors and hedge funds own 88.72% of the company’s stock.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Recommended Story: What is a Real Estate Investment Trust (REIT)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.